Announcement • Apr 01
Cenntro Inc. announced delayed annual 10-K filing On 03/31/2026, Cenntro Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. New Risk • Mar 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.49m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$20m free cash flow). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (185% increase in shares outstanding). Market cap is less than US$10m (US$9.49m market cap). Announcement • Jan 01
Cenntro Inc. Announces Board Changes, Effective December 23, 2025 Cenntro Inc. announced that on December 22, 2025, Mr. Gang “Gavin” Lin, the independent director of the Company notified the Board of Directors (the “Board”) of Cenntro Inc. of his decision to resign his position as an independent director and a member of the Audit Committee of the Board, effective on December 23, 2025. To fill the vacancy created by Mr. Lin’s resignation until the Company’s next annual general meeting called for the election of directors, the Board appointed Charles Athle Nelson to serve as an independent director and a member of the Audit Committee of the Board, effective on December 23, 2025. Mr. Charles Athle Nelson has been active in the capital markets for the past 35 years. He began his financial career as a market representative with American International Group and in 1979 joined Dean Witter Reynolds as a Financial Advisor, working with high net worth and institutional clients. In 1980, he joined Drexel Burnham and Lambert, and subsequently, at Ladenberg Thalmann and then at Auerbach Pollack and Richardson originated equity and investment banking transactions. Over the last 20 years, Mr. Nelson has been involved with financing companies in the fintech, healthcare and bio-pharma spaces through private equity and public financing including listings on the Nasdaq and the NYSE. Mr. Nelson holds a bachelor’s degree in arts from Villanova University and an MBA from Rutgers University. 
